These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Human IgG1 Cgamma1 domain is crucial for the bioactivity of the engineered anti-CD20 antibodies. Geng S; Feng J; Li Y; Kang X; Sun Y; Gu X; Huang Y; Chang H; Shen BF Cell Mol Immunol; 2007 Apr; 4(2):121-5. PubMed ID: 17484806 [TBL] [Abstract][Full Text] [Related]
4. Improving the CH1-CK heterodimerization and pharmacokinetics of 4Dm2m, a novel potent CD4-antibody fusion protein against HIV-1. Chen W; Bardhi A; Feng Y; Wang Y; Qi Q; Li W; Zhu Z; Dyba MA; Ying T; Jiang S; Goldstein H; Dimitrov DS MAbs; 2016; 8(4):761-74. PubMed ID: 26963639 [TBL] [Abstract][Full Text] [Related]
5. Discovery of novel candidate therapeutics and diagnostics based on engineered human antibody domains. Chen W; Gong R; Ying T; Prabakaran P; Zhu Z; Feng Y; Dimitrov DS Curr Drug Discov Technol; 2014 Mar; 11(1):28-40. PubMed ID: 23863097 [TBL] [Abstract][Full Text] [Related]
6. Therapeutic assessment of SEED: a new engineered antibody platform designed to generate mono- and bispecific antibodies. Muda M; Gross AW; Dawson JP; He C; Kurosawa E; Schweickhardt R; Dugas M; Soloviev M; Bernhardt A; Fischer D; Wesolowski JS; Kelton C; Neuteboom B; Hock B Protein Eng Des Sel; 2011 May; 24(5):447-54. PubMed ID: 21498564 [TBL] [Abstract][Full Text] [Related]
8. Generation of dual-variable-domain immunoglobulin molecules for dual-specific targeting. Gu J; Ghayur T Methods Enzymol; 2012; 502():25-41. PubMed ID: 22208980 [TBL] [Abstract][Full Text] [Related]
9. Antibody affinity maturation in vitro using unconjugated peptide antigen. Iwai H; Oztürk B; Ihara M; Ueda H Protein Eng Des Sel; 2010 Apr; 23(4):185-93. PubMed ID: 20123883 [TBL] [Abstract][Full Text] [Related]
10. Engineering of stable bispecific antibodies targeting IL-17A and IL-23. Mabry R; Lewis KE; Moore M; McKernan PA; Bukowski TR; Bontadelli K; Brender T; Okada S; Lum K; West J; Kuijper JL; Ardourel D; Franke S; Lockwood L; Vu T; Frank A; Appleby MW; Wolf A; Reardon B; Hamacher NB; Stevens B; Lewis P; Lewis KB; Gilbertson DG; Lantry M; Julien SH; Ostrander C; Chan C; Byrnes-Blake K; Brody J; Presnell S; Meengs B; Levin SD; Snavely M Protein Eng Des Sel; 2010 Mar; 23(3):115-27. PubMed ID: 20022918 [TBL] [Abstract][Full Text] [Related]
11. Conserved amino acid networks involved in antibody variable domain interactions. Wang N; Smith WF; Miller BR; Aivazian D; Lugovskoy AA; Reff ME; Glaser SM; Croner LJ; Demarest SJ Proteins; 2009 Jul; 76(1):99-114. PubMed ID: 19089973 [TBL] [Abstract][Full Text] [Related]
12. Guided selection of a pan carcinoma specific antibody reveals similar binding characteristics yet structural divergence between the original murine antibody and its human equivalent. Beiboer SH; Reurs A; Roovers RC; Arends JW; Whitelegg NR; Rees AR; Hoogenboom HR J Mol Biol; 2000 Feb; 296(3):833-49. PubMed ID: 10677285 [TBL] [Abstract][Full Text] [Related]
13. Applications of single-chain variable fragment antibodies in therapeutics and diagnostics. Weisser NE; Hall JC Biotechnol Adv; 2009; 27(4):502-20. PubMed ID: 19374944 [TBL] [Abstract][Full Text] [Related]
14. Reduced elimination of IgG antibodies by engineering the variable region. Igawa T; Tsunoda H; Tachibana T; Maeda A; Mimoto F; Moriyama C; Nanami M; Sekimori Y; Nabuchi Y; Aso Y; Hattori K Protein Eng Des Sel; 2010 May; 23(5):385-92. PubMed ID: 20159773 [TBL] [Abstract][Full Text] [Related]
15. Humanization by variable domain resurfacing and grafting on a human IgG4, using a new approach for determination of non-human like surface accessible framework residues based on homology modelling of variable domains. Staelens S; Desmet J; Ngo TH; Vauterin S; Pareyn I; Barbeaux P; Van Rompaey I; Stassen JM; Deckmyn H; Vanhoorelbeke K Mol Immunol; 2006 Mar; 43(8):1243-57. PubMed ID: 16118019 [TBL] [Abstract][Full Text] [Related]
16. Helix-stabilized Fv (hsFv) antibody fragments: substituting the constant domains of a Fab fragment for a heterodimeric coiled-coil domain. Arndt KM; Müller KM; Plückthun A J Mol Biol; 2001 Sep; 312(1):221-8. PubMed ID: 11545598 [TBL] [Abstract][Full Text] [Related]
17. Disulfide linkage engineering for improving biophysical properties of human VH domains. Kim DY; Kandalaft H; Ding W; Ryan S; van Faassen H; Hirama T; Foote SJ; MacKenzie R; Tanha J Protein Eng Des Sel; 2012 Oct; 25(10):581-9. PubMed ID: 22942392 [TBL] [Abstract][Full Text] [Related]
18. Optimal construction of non-immune scFv phage display libraries from mouse bone marrow and spleen established to select specific scFvs efficiently binding to antigen. Okamoto T; Mukai Y; Yoshioka Y; Shibata H; Kawamura M; Yamamoto Y; Nakagawa S; Kamada H; Hayakawa T; Mayumi T; Tsutsumi Y Biochem Biophys Res Commun; 2004 Oct; 323(2):583-91. PubMed ID: 15369791 [TBL] [Abstract][Full Text] [Related]
19. Platelet integrin alpha2 I-domain specific antibodies produced via domain specific DNA vaccination combined with variable gene phage display. Hughes DL; Stafford P; Hamaia SW; Harmer lJ; Schoolmeester A; Deckmyn H; Farndale RW; Ouwehand WH; Watkins NA Thromb Haemost; 2005 Dec; 94(6):1318-26. PubMed ID: 16411412 [TBL] [Abstract][Full Text] [Related]
20. Humanization of an anti-human IL-6 mouse monoclonal antibody glycosylated in its heavy chain variable region. Sato K; Ohtomo T; Hirata Y; Saito H; Matsuura T; Akimoto T; Akamatsu K; Koishihara Y; Ohsugi Y; Tsuchiya M Hum Antibodies Hybridomas; 1996; 7(4):175-83. PubMed ID: 9140729 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]